New evidence with selective agonists and antagonists for the subclassification of PGE2-sensitive (EP) receptors.
D000527:Alprostadil / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide / Q000494:pharmacology; D015232:Dinoprostone / Q000031:analogs & derivatives; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D011458:Prostaglandins E / Q000494:pharmacology*; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology; D011982:Receptors, Prostaglandin / Q000187:drug effects*; D018078:Receptors, Prostaglandin E; D014966:Xanthenes / Q000494:pharmacology; D044004:Xanthones
D011458:Prostaglandins E; D011459:Prostaglandins E, Synthetic; D011982:Receptors, Prostaglandin; D018078:Receptors, Prostaglandin E; D014966:Xanthenes; D044004:Xanthones; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide; C053876:6-isopropoxy-9-oxoxanthene-2-carboxylic acid; C053875:AY 23626; C016767:sulprostone; D000527:Alprostadil; D015232:Dinoprostone